Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox


Recently, a new class of antiviral drugs neuraminidase inhibitors has been approved in several countries for treatment of uncomplicated influenza. These inhibitors called zanamivir and oseltamivir are active against both influenza A and B viruses. Administered within 48 hours of illness, they can reduce the severity and duration of signs and symptoms of uncomplicated Influenza. However, the US Food and Drug Administration (FDA) declared that they are no substitution for vaccination.

For any question on treatment of influenza, always consult your doctor for professional medical advice.

 » Printversion

  » find


Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine
» read more

Baxter to participate in development of cell-based vaccines for U.S. Department of Health and Human Services
» read more

Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more

Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,